Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Mylan's EpiPen Nightmare Not Over Yet, But Will Congress Just Write?

Executive Summary

Unless Republicans are convinced the market can't fix the problem, Mylan officials may only get congressional letters on the EpiPen price increase.


Related Content

Putting The Pieces Together For Combo Products Oversight
A Tale Of Two Committees: Which Probed EpiPen Better?
EpiPen Outrage In Congress Puts Spotlight On FDA Generic Review
Mylan's Generic EpiPen: A Good PR Move, But Risks Alienating Payers
Why Generic EpiPen Is Not The Answer – Until FDA Says It Is
Mylan’s EpiPen Exclusivity Saved Again As Teva Reports CRL
Eye Of The Pricing Storm: FDA's Woodcock Withstands Gale-Force Rhetoric
At Drug Pricing Hearing, Innovator Companies Mainly Escape Congressional Wrath
Could Drug Price Spikes Spur ANDA Priority Reviews?
Mylan’s EpiPen Defense Against Generics Focuses On Device Design


Related Companies